ArticleJournal of applied microbiology2020
Characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Fuzhou, China.
Article in Journal of applied microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Characterization of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Epidemiological Trends and Drug Resistance Patterns of Carbapenem-Resistant Gram-Negative Bacteria: A Retrospective Study in a Tertiary Hospital in China (2019-2024).Infection and drug resistance · 2025Article
- Molecular Epidemiological Characteristics ofInfection and drug resistance · 2025Article
- Epidemiology and clinical characteristics of patients with healthcare-acquired multidrug-resistant Gram-negative bacilli: a retrospective study from a tertiary care hospital.Scientific reports · 2024Article
- Virulence, antimicrobial resistance, and molecular characteristics of carbapenem-resistant Klebsiella pneumoniae in a hospital in Shijiazhuang City from China.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Antimicrobial Resistance Patterns, Sequence Types, Virulence and Carbapenemase Genes of Carbapenem-ResistantInfection and drug resistance · 2023Article
- ST11 Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Characterization of Tigecycline Resistance Among Tigecycline Non-susceptibleFrontiers in microbiology · 2021Article
- Analysis of Carbapenemase-Resistant Genotypes of Highly VirulentEvidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsThe emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) strains has led to increased mortality and morbidity rates. Tigecycline, a new class of broad-spectrum glycyl-tetracycline antibiotics, has been used to target multi- and pan-drug-resistant bacterial infections. This study aimed to assess the molecular characteristics of CRKP in a tertiary hospital, and its susceptibility to tigecycline, to create a reference for hospital infection control and clinical drug use. METHODS AND
resultsWe retrieved patient clinical information and CRKP characterization from medical records and detected the MIC of tigecycline using the micro-broth dilution method. Multi-locus sequence typing was performed, and antibiotic resistance genes associated with CRKP were detected by qPCR. A total of 166 CRKP strains were detected in the sputum, urine and blood among intensive care unit patients (average age, 69·6 years). The most infrequently observed resistance genes were amikacin resistance genes, followed by tobramycin resistance genes. KPC-2, CTX-M9 and CTX-M1 were the most frequently detected resistance genes.
conclusionsNo strain was resistant to tigecycline (MIC ≥ 8 µg ml SIGNIFICANCE AND IMPACT OF THE STUDY: Clinicians and infection control experts should be aware of CRKP prevalence to facilitate clinical treatment and improve nosocomial infection control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.